Comprehensive Guide to Mitomycin 10mg Injection In the complex field of chemotherapy, Mitomycin 10mg Injection (also known as Mitomycin-C) remains a vital cytotoxic antibiotic used to treat various resistant adenocarcinomas. As a premier pharmaceutical exporter from India, Ernest Oncology (a group of Ernest Pharmaceutical Pvt. Ltd.) ensures the seamless supply of this critical medication to healthcare providers in London, New York, Sydney, Johannesburg, and beyond. Product Specifications Brand Name: Ernest-Oncology (Mitomycin) Strength: 10 mg per vial Dosage Form: Lyophilized Powder for Injection Primary Indication: Gastric and Pancreatic Adenocarcinoma, Bladder Cancer (Intravesical). Storage: Store at controlled room temperature (20°C to 25°C). Protect from light. Mechanism of Action: How It Works DNA Cross-linking: Once activated within the cell, Mitomycin produces bifunctional and trifunctional alkylation, leading to the cross-linking of DNA strands. Inhibition of Synthesis: This process inhibits DNA synthesis and, to a lesser extent, RNA and protein synthesis, effectively preventing cancer cells from replicating and causing cell death. Therapeutic Indications & Administration Disseminated Adenocarcinoma: Often used in combination with other chemotherapeutic agents for stomach and pancreatic cancers when other treatments have failed. Superficial Bladder Cancer: Administered intravesically (directly into the bladder) to treat or prevent recurrence of tumors. Ophthalmic Use: In low concentrations, it is sometimes used during glaucoma surgery to prevent scarring. Administration: Intravenous (IV): Must be administered by a qualified professional. It is a potent vesicant; extreme care must be taken to avoid extravasation, which can cause severe tissue necrosis. Dosing: Typically 20 mg/m² intravenously as a single dose every 6–8 weeks, depending on bone marrow recovery. Clinical Side Effects & Safety Bone Marrow Suppression: The most serious side effect. It is often delayed and cumulative, resulting in low white blood cells (leukopenia) and platelets (thrombocytopenia). Hemolytic Uremic Syndrome (HUS): A rare but serious condition involving microangiopathic hemolytic anemia and renal failure. Pulmonary Toxicity: May cause shortness of breath or non-productive cough; lung function should be monitored. Common Effects: Nausea, vomiting, hair loss (alopecia), and loss of appetite. Contraindications: Not for patients with hypersensitivity, coagulation disorders, or severe bone marrow depression. Why Source from Ernest Oncology? United Kingdom (London): Meeting the demand for specialized oncology generics in private and public sectors. USA: Bulk supply solutions adhering to international safety and documentation standards. Australia: Reliable access through the “Special Access Scheme“ (SAS) and hospital procurement. South Africa: Bridging the gap in oncology care with cost-effective, high-tier Indian pharmaceutical exports. 📞 Contact Ernest Oncology — Pharmaceutical Exporter from India [GROUP OF ERNEST PHARMACEUTICAL PVT. LTD.] 📦 Business Type: Exporter | Bulk Supplier | Distributor 🌐 Websites: www.oncologymedicinesupplier.com www.ernestpharmaceuticals.com www.ernestvision.com www.ernestimpex.com 📧 Email: exports@ernestpharmaceuticals.com 📲 WhatsApp: +91 93599 02383 🔗 Direct Link: https://wa.me/919359902383
Washington, USA
08048034998
+919405476170
Chat with us
Chat with us